SC Memorial Healthcare International SRL

Bucharest 013823

4 studies enrolling now · 7 studies all time

What they study most

Abiraterone Acetate, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Drug-Related Side Effects and Adverse Reactions, Enzyme Inhibitors, Fallopian Tube Neoplasms

Studies at this site

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling